Evogene Ltd (EVGN)
EVGN trades on Nasdaq in Industrials, Agricultural Chemicals. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (ifrs-full:Revenue), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1574565/000117891326001767/0001178913-26-001767-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLossAttributableToOwnersOfParent), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | EVGN on Nasdaq |
| Sector | Industrials |
| Industry | Agricultural Chemicals |
| Country | Israel |
| IPO year | Not reported by the screener |
| SEC CIK | 0001574565 |
| SEC industry code | Agricultural Chemicals |
| Incorporated in | Israel |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $3.9M |
| Net income | -$8.5M |
| Operating income | -$14.0M |
| Net margin | -220.2% |
| Operating margin | -364.2% |
| Revenue growth | -30.9% |
| Cash | $13.0M |
| Total assets | $20.0M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 1.6× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "We concluded that the following conditions raised substantial doubt about our ability to continue as a going concern: - History of reporting operating losses from continuing operations of $14,034 and $18,804 for the years ended December 31, 2025, and 2024, respectively; - Net operating cash outflows of $13,502 and $19,700 in 2025 and 2024, respectively; - The Company's Accumulated Deficit balance as of December 31, 2" | 20-F 2026-03-26 |
| Cash and burn | $13.0M cash; operating cash flow -$3.4M a quarter. | Report 2025-12-31 |
| Shares outstanding | 8,718,193 (2025-12-31); 6,514,589 a year earlier; 41,260,439 three years earlier. 3y figure adjusted for split (1-for-10 overall); the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures. | Cover page 2025-12-31 |
| Reverse splits, 3 years | 1; latest 1-for-10 on 2024-07-25 | Source 2024-07-25 |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the market | Latest 2026-07-17 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Kost Forer Gabbay & Kasierer, Tel Aviv, Israel | PCAOB Form AP 2026-04-26 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $695K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
| Market cap check | The listing's market cap implies 15,801,407 shares at the 2026-11-13 price; the latest SEC cover count is 8,718,193 as of 2025-12-31. The SEC count is the older of the two, so the listing's cap is likely the current one; shares were issued since that cover page. | Nasdaq screener and SEC cover page |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-12-31 | $3.9M | -$8.5M | -$13.5M | $13.0M | No debt tags | $3.9M | 20-F 2026-03-26 |
| FY 2024 2024-12-31 | $5.6M | -$16.5M | -$19.7M | $15.3M | No debt tags | $5.6M | 20-F 2026-03-26 |
| FY 2023 2023-12-31 | $3.0M | -$23.9M | -$21.6M | $20.8M | No debt tags | $3.0M | 20-F 2026-03-26 |
| FY 2022 2022-12-31 | $1.7M | -$26.6M | -$23.7M | $29.0M | No debt tags | $1.7M | 20-F 2025-03-27 |
| FY 2021 2021-12-31 | $930K | -$27.8M | -$24.7M | $32.3M | No debt tags | $930K | 20-F 2024-03-28 |
| FY 2020 2020-12-31 | $1.0M | -$23.4M | -$19.5M | $46.2M | No debt tags | $1.0M | 20-F 2023-03-30 |
| FY 2019 2019-12-31 | $753K | -$18.1M | -$17.7M | $34.7M | No debt tags | $753K | 20-F 2022-03-31 |
| FY 2018 2018-12-31 | $1.7M | -$20.8M | -$15.2M | $5.8M | No debt tags | $1.7M | 20-F 2021-04-02 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | POS AM | 2026-09-28 |
| Latest annual report | 20-F | 2026-03-26 |
| Latest quarterly / interim | 6-K | 2026-11-16 |
Source: SEC EDGAR submissions feed, 465 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +37.0% |
| 1 month | -5.1% |
| 3 months | -43.1% |
| Year to date | -66.4% |
| 1 year | -68.9% |
| From 52-week high | -69.4% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Agricultural Chemicals
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| FRTT | Fort Technology Inc. Common Shares | $0.3800 | -4.43% | $5.7M |
| SNES | SenesTech Inc. | $0.7725 | -10.38% | $5.3M |
| BIOX | Bioceres Crop Solutions Corp. | $0.1997 | -4.95% | $12.7M |
| AVD | American Vanguard Corporation Common Stock ($0.10 Par Value) | $0.7615 | -13.07% | $22.5M |
| NXTS | Nexentis Technologies Inc. | $1.99 | -9.55% | $1.3M |
| CBUS | Cibus Inc. | $1.20 | +6.19% | $92.0M |
| UAN | CVR Partners LP Common Units representing Limited Partner Interests | $103.65 | -6.46% | $1.1B |
| SMG | Scotts Miracle-Gro Company (The) | $63.76 | -0.13% | $3.7B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier